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JO Bay,1 A. Cabrespine,1 C. Faucher,2 R. Tabrizi,3 P. Bordigoni,4 A. Berceanu,5 V. Coiteux,6
M. Renaud,7 V. Mialou,8 M. Robin,9 M. Kuentz,10 P. Chevallier,11 N. Dhedin,12 A. Huynh,13
F. Garban,14 F. Witz,15 A. Buzyn,16 T. De Revel,17 C. Galambrun,18 E. Deconinck,19
N. Contentin,20 S. Franc¸ois,21 N. Gratecos,22 D. Blaise,23 M. Michallet,24 on behalf of the
Societe Franc¸aise de Greffe de Moelle et de Therapie CellulaireThe purpose of this paper is to describe the outcome of patients who underwent double allogeneic hema-
topoietic stem cell transplantation (AHSCT) with reduced-intensity conditioning regimens (RIC). Forty-five
patients who received double RIC-AHSCT between 1997 and 2006 were retrospectively studied. The pre-
dominant diagnosis was acute myeloid leukemia (AML) (n5 17). Other diagnoses were aplasic anemia (AA)
(n5 5), myelodysplasic disorder (n5 5), acute lymphoblastic leukemia (ALL) (n5 4), chronic myelomono-
cytic leukemia (CML) (n5 3), myeloma (n5 3), non-Hodgkin lymphoma (NHL) (n5 3), chronic lymphocytic
leukemia (CLL) (n5 2), Hodgkin’s disease (HD) (n5 2), and chronic myelomonocytic leukemia (n5 1). Main
indications for RIC-AHSCT 2 were relapse (n5 25, 56%) and early (n5 8, 18%) or late (n5 12, 26%) graft
failure. Median delays to reach a neutrophil count of 0.5  109/L and platelet counts of 50  109/L were sig-
nificantly smaller after the second AHSCT. Among 25 patients who relapsed after RIC-AHSCT 1, 14 patients
(56%) presented a response improvement after RIC-AHSCT 2. In this group, 9 patients sustained a complete
response and 5 patients a partial response. Moreover, among the 20 patients who had early or late graft fail-
ure following RIC-AHSCT 1, 9 (45%) finally reached an engraftment. Disease-free survival (DFS) was signif-
icantly improved after RIC-AHSCT 2. Thirteen patients (28%) died of transplant-related mortality (TRM) at
a median delay of 69 days (range: 0-451) after RIC-AHSCT 2. Double RIC-AHSCT is a feasible procedure that
allows a response or engraftment not observed after RIC-AHSCT 1. Themain indication is relapse. However,
TRM remains high.
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Allogeneic hematopoietic stem cell transplantation
(AHSCT) provides a potential long-term curative op-
tion for patients affected by hematologic malignancies.
Subsets of patients, however, fail to achieve durable
remission. Acute or chronic graft-versus-host disease
(aGVHD, cGVHD) or infections, disease relapse,
and engraftment failure are significant causes of initial
treatment failure. One of the treatments for relapse or
engraftment failure can be a second AHSCT. Graft
combinations were initially shown in dose density/
dose intensity strategies described in testicular germ
cell tumors [1] or in tandem autologous transplanta-
tion in high-risk multiple myeloma [2]. More specifi-
cally in multiple myeloma, autologous stem cell
transplantation followed by dose-reduced AHSCT
was also assessed [3]. A second AHSCT is not rare
in patient management care that had previously
comprised an AHSCTwith a myeloablative (MA) con-
ditioning regimen [4-6]. The use of a second AHSCT
procedure, applying MA conditioning, was reportedly
associated with improved disease-free survival (DFS)
at the price of greatly increased rates of transplant-
related mortality (TRM) [7].
Reduced-intensity conditioning (RIC) became pro-
gressively a standard therapeutic treatment for patients
who could not receive conventional AHSCTbecause of
age or unsuitable comorbidity. Second RIC-AHSCT
had been associated with a low TRM in patients who
have undergone a previous autologous transplantation
[8]. Recently, Shaw et al. [4] had confirmed that the
use of RIC for the second AHSCT when disease re-
lapses following the first procedure results in a low
and acceptable TRM. These results lead us to wonder
about the indication and the potential interest of an
approach with 2 consecutives RIC-AHSCT.
Few centers of the ‘‘Societe Franc¸aise de Greffe de
Moelle et deTherapieCellulaire’’ (SFGM-TC) had re-
alized successively with successively 2 RIC-AHSCTs
regimens. Because indication remains limited in each
transplant center, a retrospective study was necessary
in order to describe the indications of the second
RIC-AHSCT and outcome of the patients. Therefore,
we performed a multicentric retrospective analysis of
45 patients who consecutively received 2 RIC-
AHSCTs. These data were recorded in the registry of
the SFGM-TC.DESIGN AND METHODS
Selection of Patients
Patients fulfilling the requirements for this study
were identified from the database held by the SFGM-
TC registry. This multicenter retrospective study
included all patients who underwent 2 consecutiveRIC-AHSCTs. No selection criterion other than the
use of 2 RIC for 2 consecutive AHSCT was selected
for the purpose of this study. All patients gave written
informed consent regarding the RIC-AHSCT. RIC
was defined by the center at time of data submission
as an association of the use of fludarabine with low-
dose total body irradiation (TBI #4 Gy), or busulfan
(total dose #8 mg/kg), or other immunosuppressive
or chemotherapeutic drugs, such as melphalan or cy-
clophosphamide [9]. GVHD prophylaxis and support-
ive care were applied according to institutional
procedures. They all received their AHSCTs between
1997 and 2006.
This study was approved by the scientific com-
mittee of the SFGM-TC. Information concerning
donors, recipients, conditioning regimen, graft har-
vesting, and follow-up were collected by transplant
centers using prospectively designed forms from the
Promise (European group for Blood and Marrow
Transplantation [EBMT] Central Registry Office,
London) database. All centers were also contacted to
improve the database. Forty-five patients from 21
transplant centers were identified and included.Evaluations
All the follow-up evaluations were carefully
reported and analyzed for each patient and after each
RIC-AHSCT.
Engraftment
Time to neutrophils engraftment was defined as
the first of 3 consecutive days on which neutrophils
exceeded 0.5  109/L. Time to platelet engraftment
was defined as the first of 3 days with 50 109/L plate-
lets without platelet transfusion during a 5-day period.
Engraftment was evaluated for unsorted peripheral
blood and bone marrow cells by assessing hematopoi-
etic chimerism in allogeneic recipients on days 30, 60,
and 90, and before and after donor lymphocyte infu-
sions (DLI) if performed. Conventional cytogenetic
analyses were performed for sex-mismatched donor-
recipient pairs and polymerase chain reaction (PCR)-
based analyses of variable number of tandem repeat
(VNTR) polymorphisms were performed for sex-
matched cases. Complete donor chimerism was de-
fined as the presence of 99% or higher donor DNA
as detected by the PCR. Mixed chimerism was defined
as at least 1% recipient DNA as detected by the PCR-
assay [10].
Primary graft failure was defined as patients
who did not reach a neutrophil count $0.5  109/L
for 3 consecutive days by day 28 after AHSCT.
Late graft failure was defined as patients who demon-
strated evidence of initial engraftment followed by
development of a neutrophil count \0.5  109/L
for at least 14 days 5 [11].
Table 1. Patient’ Characteristics (n 5 45)
Median age at first transplantation (years) 45 [range 13-65]
Pediatric patients (age #18 years) n, % 2 (4%)
Sex ratio (man/woman) n, % 30 (65%)/16 (35%)
Median delay between diagnosis and first
AHSCT (months)
25.1 [range 2.7-163.7]
Median delay between both AHSCT (months) 8.4 [range 1.4-61]
Diagnosis according to RIC-AHSCT 2 indication
GF: n, %/R: n, %
AML 7* (42)/10(58)
Aplasic anemia 5 (100)/0 (0)
Myelodysplasic disorder 2 (40)/3(60)
ALL 1 (25)/3(75)
CML 1 (50)/1(50)
Myeloma 0 (0)/3(100)
NHL 2 (67)/1(33)
CLL 0 (0)/2(100)
Hodgkin’s disease 1 (50)/1(50)
CMML 1 (100)/0(0)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leuke-
mia; CML, chronic myelomonocytic leukemia; NHL, non-Hodgkin lym-
phoma; CLL, chronic lymphocytic leukemia; CMML, chronic
myelocytic leukemia; GF, graft failure; R, relapse.
*Including 3 of secondary origin.
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Response was assessed according to standardized
response criteria applicable for each pathology and ini-
tial diagnosis.
Toxicities
Toxicities were retrospectively evaluated for treat-
ment safety according to the National Cancer
Institute-Common Toxicity Criteria (NCI-CTC)
common toxicity criteria. TRM included all causes of
death other than disease relapse or progression occur-
ring at any time after transplantation.
GVHD
The severity of aGVHD was graded according
to the Glucksberg scale [12]. The Seattle group sys-
tem was used for grading cGVHD as limited or ex-
tensive [13].
Survival
Overall survival (OS) was calculated from the date
of transplantation to either the date of death from any
cause or last follow-up. DFS was calculated from the
date of AHSCT to the date of relapse or last follow-up.
Statistical Analysis
Descriptive statistics were used to characterize the
population, including themedian and range. Survival es-
timates were determined using the Kaplan-Meier
method. Univariate analysis was performed to compare
hematopoietic reconstitution, aGVHD incidence,
infection-related complications, noninfection-related
complications, and DFS between both RIC-AHSCT
using the chi-square test for qualitative analysis, the
Kruskal-Wallis test for quantitative analysis, and the
log-rank test for survival comparison. Statistical signifi-
cance was considered at P\ .05. Data analysis was per-
formed using Stata Software (version 10, StataCorp,
College Station, TX).RESULTS
Patients’ Characteristics
We analyzed a total of 45 patients. The median age
of the population was 45 years (range: 13-65) (Table 1).
Sixty-five percent of patients were male. Four percent
of patients were pediatric patients defined as age under
18 years. The predominant diagnosis was acute
myeloid leukemia including 3 of secondary origin
(n 5 17). Other diagnoses were aplasic anemia
(AA) (n 5 5), myelodysplasic disorder (n 5 5), acute
lymphoblastic leukemia (ALL) (n 5 4), chronic
myelomonocytic leukemia (n 5 3), myeloma (n 5 3),
non-Hodgkin lymphoma (NHL) (n5 3), chronic lym-
phocytic leukemia (CLL) (n 5 2), Hodgkin disease(HD) (n 5 2), and chronic myelomonocytic leukemia
(n 5 1). The main indications for RIC-AHSCT 2
were relapse (n 5 25, 56%) and early (n 5 8, 18%)
or late (n5 12, 26%) graft failure. Diagnosis according
to RIC-AHSCT 2 indication highlighted that patients
with AA underwent RIC-AHSCT 2 only for graft fail-
ure. The median delay between diagnosis and first
RIC-AHSCT and between both RIC-AHSCTs was
25.1 months (range: 2.7-163.7) and 8.4 months (range:
1.4-61), respectively.Transplant-Related Characteristics
As summarized in Table 2, the majority of patients
were in complete response before RIC-AHSCT 1
and 2. Five patients were not evaluable corresponding
to AA. If patients failed to engraft after RIC-AHSCT
1, the conditioning regimen, GVHD prophylaxis,
donors, and source of the stem cells were changed
for 95%, 65%, 45%, and 50% of patients for RIC-
AHSCT 2, respectively. Similarly, if the RIC-
AHSCT 2 indication was relapse, the source of stem
cell, conditioning regimen, GVHD prophylaxis, and
donors were changed for 96%, 68%, and 52% of
patients, respectively. The 2 most widely used condi-
tioning regimens were fludarabine 1 busulfan 1
antithymocyte globulin (ATG), and fludarabine 1
reduced-intensity TBI. The other conditioning regi-
mens used were mainly fludarabine-based, either alone
or in combination. Immunosuppression was mainly
based on cyclosporine (CsA) alone for RIC-AHSCT
1 and was intensified for RIC-AHSCT 2with a combi-
nation of mycophenolate mofetil (lMMF) or metho-
trexate (MTX).
One patient who relapsed between the 2 AHSCTs
had received a reinduction and 7 had received DLI.
Table 2. Transplant-Related Characteristics According to RIC-AHSCT 1 and 2 and RIC-AHSCT-2 Indication
Graft Failure (n 5 20) Relapse (n 5 25)
RIC-AHSCT 1 RIC-AHSCT 2 RIC-AHSCT 1 RIC-AHSCT 2
Disease status at transplant n, %
CR 7 (35) 6 (30) 15 (60) 8 (32)
PR 1 (5) 1 (5) 4 (16) 4 (16)
SD 0 (0) 1 (5) 0 (0) 3 (12)
PD/Relapse/induction failure 5 (25) 5 (25) 4 (16) 8 (28)
CPh 2 (10) 2 (10) 2 (8) 1 (4)
APh 0 (0) 0 (0) 0 (0) 1 (4)
NE 5 (25) 5 (25) 0 (0) 1 (4)
Conditioning regimen n, % Changed: 19 (95%) Changed: 24 (96%)
Fludarabine + Busulfan ± ATG 4 (20) 3 (15) 11 (44) 5 (20)
Fludarabine + TBI (2Gy) 5 (25) 2 (10) 6 (24) 9 (36)
Fludarabine alone ± ATG 2 (10) 3 (15) 0 (0) 1 (4)
Other Fludarabine-based regimen 9 (45) 12 (60) 8 (32) 10 (40)
GVHD prophylaxis n, % Changed: 13 (65%) Changed: 17 (68%)
CsA alone 12 (60) 11 (55) 12 (48) 10 (40)
CsA + MMF 5 (25) 7 (35) 6 (24) 6 (24)
CsA + methotrexate 2 (10) 1 (5) 7 (28) 6 (24)
Other 1 (5) 1 (5) 0 (0) 3 (12)
Donor n, % Changed: 9 (45%) Changed: 13 (52%)
HLA-identical 9 (45) 10 (50) 19 (74) 16 (64)
HLA-matched 6 (30) 5 (25) 4 (15) 4 (16)
HLA-mismatched 5 (25) 5 (25) 3 (11) 5 (20)
Source of stem cells n, % Changed: 10 (50%) Changed: 5(20%)
Peripheral blood 9 (45) 17 (85) 20 (80) 21 (84)
Bone marrow 8 (40) 2 (10) 3 (12) 2 (8)
Cord blood 3 (15) 1 (5) 2 (8) 2 (8)
CR indicates complete response; PR, partial response; SD, stable disease; PD, progressive disease; CPh, chronic phase; APh, accelerated phase; NE, not
evaluable; ATG, antithymocyte globulin; CsA, cyclosporin A; MMF, mycophenolate mofetil; RIC-ASCT, reduced-intensity allogeneic hematopoietic stem
cell transplantation; TBI, total body irridiation.
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1 and 2
As detailed in Table 3, the median delay to reach
a neutrophils count of 0.5  109/L and a platelets
count of 50  109/L were significantly lower after
the second RIC-AHSCT (21 days [range: 0-250] vs
16 days [range: 0-104], P 5 .0031 and 21 days [range:
0-246] vs 13 days [range: 0-46], P 5 .0034). Nine
(20%) and 13 patients (29%) were never below 0.5 
109/L neutrophils after AHSCT 1 and 2, respectively.
Eleven (24%) and 16 patients (36%) were never below
50  109/L platelets after AHSCT 1 and 2, respec-
tively. Neutrophils 0.5  109/L were not reached
only for 1 patient (2%) after AHSCT 2. PlateletsTable 3. Comparative Outcome after RIC-AHSCT 1 and RIC-AHS
RIC-AH
Median delay to reach neutrophils >0.5  109/L (day) 21 (range
Median delay to reach platelets >50  109/L (day) 21 (range
aGVHD n,% 12 (27%)
aGVHD grade III-IV n, % 1 (2%)
Infection-related complication n, % 15 (33%)
Noninfection-related complications n, % 10 (22%)
Median DFS (months) 8 (range
aGVHD indicates acute graft-versus host disease; DFS, disease-free survival; RI
cell transplantation.
Bold values are significant values.
*Never below for 9 patients.
†Never below for 11 patients and never reached for 1 patient early dead of t
‡Never below for 13 patients and never reached for 2 patients who presente
§Never below for 16 patients and never reached for 1 patient early dead of to50 109/L were not reached for 2 (4%) and 1 patients
(2%) after AHSCT 1 and 2, respectively. Although the
aGVHD incidence appeared similar after both RIC-
AHSCTs (27% vs 38%), the aGVHDgrade III-IV fol-
lowing RIC-AHSCT 2 was slightly higher (2% vs
13%, P 5 .12). The aGVHD rate after the second
AHSCTwas not associated with a lower risk of relapse
rate (P5 .65). The infection-related complication rate
was significantly higher after RIC-AHSCT 2 (33% vs
56%, P 5 .034). The noninfection-related complica-
tions seemed to be higher after RIC-AHSCT 2 (22%
vs 40%, P 5 .069), but the difference just failed to
reach statistical significance. DFS was significantly im-
proved after RIC-AHSCT 2 (8months [range: 0-44] vsCT 2
SCT 1 RIC-AHSCT 2 P Value
: 0-250)* 16 (range: 0-104)† .0031
: 0-46)‡ 13 (range: 0-46)§ .0034
17 (38%) .26
6 (13%) .12
25 (56%) .034
18 (40%) .069
: 0-44) 24 (0-120) .0063
C, reduced-intensity conditioning; AHSCT, allogenic hematopoietic stem
oxicity.
d late graft failure.
xicity.
Figure 1. OS after both consecutive RIC-AHSCTs according to RIC-
AHSCT 2 indication. Median follow-up was at 87 months (range 47-
156). MedianOS was at 14 months (range: 3-129) and 30 months (range:
3-141) in patients given second AHSCT for graft failure (1) and for dis-
ease relapse (2), respectively. Three-year OS rate was at 40% (95% CI:
18-61) and 48% (95% CI: 28-68) in patients who have graft failure and
for disease relapse indication for RIC-AHSCT 2, respectively. RIC indi-
cates reduced-intensity conditioning; AHSCT, allogeneic hematopoietic
stem cell transplantation.
Figure 2. Transplant-related mortality rate after both consecutive
RIC-AHSCT; 13 patients died of toxicity relative mortality (TRM)
(28%; 95% CI: 15-41) at a median delay of 69 days (range 0-451) after
RIC-AHSCT 2. TRM rate following the second transplantation was
19% (95%, CI: 7-30) and 26% (95% CI: 13-39) at day 100 and 1 year, re-
spectively.
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after RIC-AHSCT 2 was 43%.
Among 25 patients who relapsed after RIC-
AHSCT1, 14 patients (56%) presentedwith a response
improvement after RIC-AHSCT2, with 9 patients and
5 patients who underwent a complete response (CR)
and partial response (PR), respectively. In the 9 patients
who enjoyed a sustained complete response, the main
diagnosis was acute myeloid leukemia (AML) (55%)
and the same donor as RIC-AHSCT 1 (89%) was fre-
quently used. Moreover, among the 20 who had early
or late graft failure following RIC-AHSCT 1, 9
(45%) finally reached an engraftment. In this early or
late graft failure, in 7 out of 9 patients (77%) the condi-
tioning regimen was not changed. Fludarabine and 2-
Gy TBI conditioning was frequently used (33%).
Survival
Median follow-up was 87 months (range: 47-156).
Median OS was 14 months (range: 3-129) and 30
months (range: 3-141) in patients given a second
AHSCT for graft failure and for disease relapse,
respectively. The three-year OS rate was 40% (95%
confidence interval [CI]: 18-61) and 48% (95% CI:
28-68) in patients who had graft failure and for disease
relapse indication for RIC-AHSCT 2, respectively
(Figure 1). Among 11 patients (24%) still alive, only
1 patient presented with a relapse and 7 patients are
still in complete response. Four long-term survivors
had received AHSCT 2 because of relapse and the 7
others because of early or late graft failure. Twenty-one patients (46%) died from progression disease
and 1 patient of a secondary malignancy. Time to re-
lapse following the first transplantation (above or be-
low median, 9 months) seemed to be correlated with
better outcomes, with a median OS of 51 months
(range: 18-141) in those who relapsed late compared
with 21 months (range: 2-129) in those who relapsed
early, but the difference failed to reach statistical sig-
nificance (P 5 .12).
Thirteen patients (28%) died of TRM at a median
delay of 69 days (range: 0-451) after AHSCT 2
(Figure 2). TRM rate was 19% (95% CI: 7-30) and
26% (95% CI: 13-39) at day 100 and 1 year,
respectively. The main causes of TRM were infections
(n 5 6: 2 fungal at days 46 and 176, 1 bacterial at day
138, and 3 unknown at days 72 and 304-451) and
lung failure (n 5 3: 2 acute respiratory distress syn-
dromes at days 1 and 22, and 1 interstitial pneumonitis
at day 20). Moreover, 1 multiorgan failure, 1 veno-
occlusive disease (VOD), 1 rejection/poor graft func-
tion, and 1 infarct-related death occurred at days 12,
28, 69, and 76, respectively. Age did not play a role
in the outcomes (data not shown).DISCUSSION
There is a large amount of published experience
regarding the use of second MA AHSCT to treat dis-
ease relapse or allograft failure following the first trans-
plantation [7,14,15]. Historically, such an approach
was complicated by high rates of TRM, and even in
recent studies this TRM rate was reportedly between
28 and 46% [14-17]. To reduce this high TRM, the
use of RIC as a conditioning regimen for a second
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[4,17,18]. Pawson et al. [18] reported the outcomes in
14 patients treatedwith a fludarabine and high-dose cy-
tarabine-containing conditioning regimen for relapse
following a sibling allograft with anMyeloablative con-
ditioning regimen. This approach was well tolerated,
with no treatment-related deaths observed at the
time of the report. A large study of 279 patients
from the International Bone Marrow Transplant Reg-
istry reported the outcomes of second allografts, in-
cluding 45 patients who had RIC following a first
AHSCT with an MA conditioning regimen. Accord-
ing to this study, the overall TRM was 26 and 30%
at 1 and 5 years, respectively, with no specific com-
ment on the effect of RIC at the second transplanta-
tion. Unlike our report, this study was concerned
with sibling transplants [17], and this may explain
the relatively low rate of TRM as it should have
been expected. Recently, Shaw et al. [4] performed
a retrospective national multicenter study in the
United Kingdom on 71 patients receiving a second
allogeneic transplant using RIC after disease relapse
following an initial allogeneic transplant which
was a RIC in 23% of cases. As in our study, TRM
appeared low at 1 year, with a cumulative incidence
of 24%. TRM improvement by the second RIC-
AHSCT was confirmed by Hill et al. [19]. They
analyzed 98 patients who underwent a second trans-
plantation using allogeneic donors at the Cleveland
Clinic. They showed that the patients whose second
transplantation was MA had significantly higher rates
of nonrelapse mortality (NRM) (64.1% vs 32.4%, P5
.021) than the patients whose second AHSCT was
RIC. First AHSCT was either autologous or alloge-
neic. Although it included 1 infarct, the TRM value
of our current study with homogeneous double RIC-
AHSCT was consistent with these previous reports.
The TRM rate after double RIC-AHSCT was lower
than the other combined AHSCTs but still remains
high even with an RIC. There is no place for an
MAC regimen as a second conditioning regimen for
those patients. Although this approach improves
TRM, the decision to undergo a second transplanta-
tion has to be pondered with the associated comorbid-
ities that can contribute to TRM [20].
As previously outlined, 2 main circumstances after
a first AHSCT warrant the discussion of a second
AHSCT: (1) graft failure and (2) disease relapse with-
out graft dysfunction [7]. In the current study, these
main indications were corroborated. Second RIC-
AHSCT showed a potential efficacy in these indica-
tions with a response improvement for 56% of patients
and 45% of engraftment after early or late graft failure
following RIC-AHSCT 1. Gyurkocza et al. [21]
showed a better engraftment rate after RIC-AHSCT
2 with fludarabine and 3- or 4-Gy TBI. However, re-
sults are difficult to compare because the first AHSCTconsisted not only of nonmyeloablative conditioning
but also myeloablative conditioning. Moreover, the
significant impact on the DFS on outcome is consis-
tent with other reports [4,17]. Double RIC-AHSCT
seems to be effective with long-term survivors. Time
to relapse was previously described as a significant fac-
tor in determining outcome and correlating a worse
OS with relapse at either\1 year [15,22],\136 days
[23], or\6months [24].We also observed a time to re-
lapse after RIC-AHSCT 1 influence, with a tendency
toward OS being better in patients who relapsed late
(.9 months). In our study, the relapse rate after
RIC-AHSCT 2 was 43% compared with 41% ob-
served after an RIC [25]. The overall survival (OS) is
poor. Most of the time, the decision concerning a sec-
ond transplantation is difficult, especially in the case of
relapse. The data confirm that there are few candidates
for second transplantation, mainly patients who did
not relapse early post-AHSCT1 with excellent com-
plete remission and good performance status.
To date, there are only heterogeneous retrospec-
tive studies that have studied second AHSCT. Our
study also remains limited because of the relative het-
erogeneity of diagnosis and the conditioning regimen.
It is possible that a significant number of inherent se-
lection biases exist because of the retrospective nature
of the studies and the small sample size. Patients se-
lected for the second allograft were obviously a favor-
able subset of patients. However, this study was
a descriptive study to investigate the indication of
RIC-AHSCT 2. Constitution of both groups, that is,
graft failure and relapse, is already a result. Tandem
is a feasible procedure but it is difficult to provide clear
recommendations. A prospective study is required to
clearly define the potential role of double RIC-
AHSCT. However, it might be difficult to define
which patients may need this tandem.
In conclusion, double RIC-AHSCT is a feasible
procedure with satisfactory graft performance that al-
lows a response or engraftment not observed after
RIC-AHSCT 1. The main indication is relapse. How-
ever, TRM remains high. New strategies, such as new
immunosuppressive drugs with lower toxicities or
monoclonal antibodies to target GVHD cells, could
lead to reducing TRM.AUTHORSHIP STATEMENT
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